Making crime pay: Alkermes aims to treat prison overcrowding
This article was originally published in Scrip
Executive Summary
Alkermes' CEO Richard Pops says he feels a "certain inevitability" over the success of its addiction drug Vivitrol (naltrexone extended-release), despite the fact that sales have been slow. In the US, reveals Mr Pops, Vivitrol is receiving "more and more interest from the criminal justice system including drug courts and state authorities".
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.